Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김충종 | * |
dc.date.accessioned | 2024-02-06T16:31:18Z | - |
dc.date.available | 2024-02-06T16:31:18Z | - |
dc.date.issued | 2024 | * |
dc.identifier.issn | 1201-9712 | * |
dc.identifier.other | OAK-34513 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/267056 | - |
dc.description.abstract | Objective: EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the longer-term antibody response of the vaccine. Methods: To assess immunogenicity 6 and 12 months after vaccination, participants in the Phase 2 trial (NCT04783311) were excluded if they: 1) withdrew, 2) reported COVID-19 infection or additional vaccination, or 3) exhibited increasing Spike (S) antibodies (representing possible non-reported infection). Following exclusions, of the 197 initial subjects, anti-S IgG antibodies and neutralizing antibodies were further assessed in 124 subjects at the 6-month timepoint, and 36 subjects at the 12-month timepoint. Results: Median anti-S antibody half-life was 52 days (interquartile range [IQR]:42-70), in the “early” period from 3 weeks to 6 months, and 130 days (IQR:97-169) in the “late” period from 6 to 12 months. There was a negative correlation between initial antibody titer and half-life. Anti-S and neutralizing antibody responses were correlated. Neutralizing antibody responses showed longer half-lives; the early period had a median half-life of 120 days (IQR:81-207), and the late period had a median half-life of 214 days (IQR:140-550). Conclusion: These data establish antibody durability of ECV-19, using a framework to analyze COVID-19 vaccine-induced antibodies during periods of high infection. © 2023 The Author(s) | * |
dc.language | English | * |
dc.publisher | Elsevier B.V. | * |
dc.subject | COVID-19 | * |
dc.subject | Durability | * |
dc.subject | Humoral immunity | * |
dc.subject | Liposome | * |
dc.subject | RBD | * |
dc.subject | SARS-CoV-2 | * |
dc.subject | Vaccine | * |
dc.title | One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects | * |
dc.type | Article | * |
dc.relation.volume | 138 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 73 | * |
dc.relation.lastpage | 80 | * |
dc.relation.journaltitle | International Journal of Infectious Diseases | * |
dc.identifier.doi | 10.1016/j.ijid.2023.11.004 | * |
dc.identifier.wosid | WOS:001130374100001 | * |
dc.identifier.scopusid | 2-s2.0-85178610942 | * |
dc.author.google | Lovell | * |
dc.author.google | Jonathan F. | * |
dc.author.google | Miura | * |
dc.author.google | Kazutoyo | * |
dc.author.google | Baik | * |
dc.author.google | Yeong Ok | * |
dc.author.google | Lee | * |
dc.author.google | Chankyu | * |
dc.author.google | Jeong-Yoon | * |
dc.author.google | Park | * |
dc.author.google | Young-Shin | * |
dc.author.google | Hong | * |
dc.author.google | Ingi | * |
dc.author.google | Jung Hyuk | * |
dc.author.google | Kim | * |
dc.author.google | Taewoo | * |
dc.author.google | Seo | * |
dc.author.google | Sang Hwan | * |
dc.author.google | Jae-Ouk | * |
dc.author.google | Song | * |
dc.author.google | Manki | * |
dc.author.google | Chung-Jong | * |
dc.author.google | Choi | * |
dc.author.google | Jae-Ki | * |
dc.author.google | Jieun | * |
dc.author.google | Choo | * |
dc.author.google | Eun Ju | * |
dc.author.google | Jung-Hyun | * |
dc.contributor.scopusid | 김충종(45361165100) | * |
dc.date.modifydate | 20240502145036 | * |